The exclusive distribution agreement is likely to have a positive impact on Ascendis Pharma's short-term stock performance due to the potential for increased sales and market presence in the Middle East. The deal opens up new markets for Skytrofa and Yorvipath, which could lead to revenue growth. However, the overall impact will depend on the market acceptance and sales performance in the new territories.